AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart

Progress in Lipid Research

Volumn 42, Issue 3, 2003, Pages 238-256

  Sambandam, Nandakumar ^a   Lopaschuk, Gary D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; GLUCOSE; PROTEIN KINASE; PROTON;

AEROBIC METABOLISM; ALLOSTERISM; BIOACCUMULATION; CARDIOMYOPATHY; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FATTY ACID METABOLISM; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLYCOLYSIS; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE REPERFUSION; HUMAN; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TISSUE DISTRIBUTION;

EID: 0037402313     PISSN: 01637827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7827(02)00065-6     Document Type: Review

References (96)

1. Heart and stroke statistical update. 2001;American Heart Association, Dallas, TX.
2. Kloner R.A., Jennings R.B. Consequences of brief ischemia. stunning, preconditioning and their clinical implications (Part 1) Circulation. 104:2001;2981-2989.
3. Lopaschuk G.D., Kantor P.F., Dyck J.R.B. Optimizing cardiac metabolism. a new reference approach to the management of ischemic heart disease? Medicographia. 21:1999;109-115.
4. Louis A.A., Manousos I.R., Coletta A.P., Clark A.L., Cleland J.G. Clinical trials update. The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II, and REMATCH Eur J Heart Fail. 4:2002;111-116.
5. Fragaso G., Piatti P.M., Monti L., Palloshi A., Lu C., Valsecchi G.et al. Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease. Evaluation of the protective role of the metabolic modulator trimetazidine. J Am Coll Cardiol. 39:2002;413-419.
6. Anderson J.R., Khou S., Nawarskas J.J. Ranolazine a potential new treatment for chronic stable angina. Heart Dis. 3:2001;263-269.
7. Wolff A.A., Rotmensch H.H., Stanley W.C., Ferrari R. Metabolic approaches to the treatment of ischemic heart disease. the clinicians' perspective Heart Fail Rev. 7:2002;187-203.
8. Winder W.W., Hardie D.G. AMP-activated protein kinase, a metabolic master switch. possible role in type 2 diabetes Am. J. Physiol. 277:1999;E1-E10.
9. Hardie D.G., Hawley S.A. AMP-activated protein kinase. the energy charge hypothesis revisited BioEssays. 23:2001;1112-1119.
10. Kudo N., Barr A.J., Barr R.L., Desai S., Lopaschuk G.D. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem. 270:1995;17513-17520.
11. Kudo N., Gillespie J.G., Kung L., Witters L.A., Schulz R., Clanachan A.S.et al. Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta. 1301:1996;67-75.
12. Marsin A.S., Bertrand L., Rider M.H., Deprez J., Beauloye C., Vincent M.F.et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischemia. Curr Biol. 10:2000;1247-1255.
13. Kantor P.F., Lopaschuk G.D., Opie L.H. Myocardial energy metabolism. Heart Physiology and Pathophysiology. 4th ed. 2001;Academic Press, London.
14. Lopaschuk G.D. Alterations in fatty acid oxidation during reperfusion of the heart after myocardial ischemia. Am J Cardiol. 80:1997;11A-16A.
15. Oliver M.F., Opie L.H. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias. Lancet. 343:1994;155-158.
16. Liu Q., Docherty J.C., Rendell J.C., Clanachan A.S., Lopaschuk G.D. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol. 39:2002;718-725.
17. Schwaiger M., Schelbert H.R., Ellison D., Hansen H., Yeatman L., Vinten-Jo-hansen J.et al. Sustained regional abnormalities in cardiac metabolism after transient ischemia in the chronic dog model. J Am Coll Cardiol. 6:1985;336-347.
18. Belke D.D., Lopaschuk G.D. Fatty acid metabolism in the reperfused ischemic heart. Adv Lipidology. 2:1997;29-46.
19. Liu B., Clanachan A.S., Schulz R., Lopaschuk G.D. Cardiac efficiency is improved after ischemia by altering both source and fate of protons. Circ Res. 79:1996;940-948.
20. Ponticos M., Lu Q.L., Morgan J.E., Hardie D.G., Partridge T.A., Carling D. Dual regulation of the AMP-activated protein kinase provides a novel mechanism for the control of creatine kinase in skeletal muscle. EMBO J. 17:1998;1688-1699.
21. Lefebvre D.L., Bai Y., Shahmolky N., Sharma M., Poon R., Drucker D.J.et al. Identification and characterization of a novel sucrose-non-fermenting protein kinase/AMP-activated protein kinase-related protein kinase, SNARK. Biochem. J. 355:2001;297-305.
22. Keith M.L., Rodwell V.W., Rogers D.H., Rudney H. In vitro phosphorylation of 3-hydroxy-3-methylglutaryl coenzyme A reductase. analysis of 32P-labeled, inactivated enzyme Biochem. Biophys. Res. Commun. 90:1979;969-975.
23. Beg Z.H., Stonik J.A., Brewer H.B. 3-Hydroxy-3-methylglutaryl coenzyme A reductase. regulation of enzymatic activity by phosphorylation and dephosphorylation Proc Natl Acad Sci USA. 75:1978;3678-3682.
24. Carlson A., Kim K.H. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J Biol Chem. 248:1973;378-380.
25. Ferrer A., Caelles C., Massot N., Hegardt F.G. Reaction of 5′-p-fluorosulfonylbenzoyladenosine with the catalytic and AMP allosteric sites of microsomal HMG-CoA reductase kinase. Biochem. Biophys. Res. Commun. 132:1985;497-504.
26. Carling D., Zammit V.A., Hardie D.G. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett. 223:1987;217-222.
27. Jiang R., Carlson M. The Snf1 protein kinase and its activating subunit, Snf4, interact with distinct domains of the Sip1/Sip2/Gal83 component in the kinase complex. Mol Cell Biol. 17:1997;2099-3106.
28. Jiang R., Carlson M. Glucose regulates protein interactions within the yeast SNF1 protein kinase complex. Genes Dev. 10:1996;3105-3115.
29. Cheung P.C.F., Salt I.P., Davies S.P., Hardie D.G., Carling D. Characterization of AMP-activated protein kinase λ subunit isoforms and their role in AMP binding. Biochem. J. 346:2000;659-669.
30. Aguan K., Scott J., See C.G., Sarkar N.H. Characterization and chromosomal localization of the human homologue of a rat AMP-activated protein kinase-encoding gene. a major regulator of lipid metabolism in mammals Gene. 149:1994;345-350.
31. Beri R.K., Marley A.E., See C.G., Sopwith W.F., Aguan K., Carling D.et al. Molecular cloning, expression and chromosomal localisation of human AMP-activated protein kinase. FEBS Lett. 356:1994;117-121.
32. Warden S.M., Richardson C., O'Donnell J. Jr., Stapleton D., Kemp B.E., Witters L.A. Post-translational modifications of the β-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. Biochem. J. 354:2001;275-283.
33. Milan D., Jeon J.-T., Looft C., Amarger V., Robic A., Thelander M.et al. A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. Science. 288:2000;1248-1251.
34. Hamilton S.R., Stapleton D., O'Donnell J.B., Kung J.T., Dalal S.R., Kemp B.E.et al. An activating mutation in the λ1 subunit of the AMP-activated protein kinase. FEBS Lett. 500:2001;163-168.
35. Franz W.M., Muller O.J., Katus H.A. Cardiomyopathies. from genetics to the prospect of treatment Lancet. 358:2001;1627-1637.
36. Blair E., Redwood C., Ashrafian H., Oliveira M., Broxholme J., Kerr B.et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy. evidence for the central role of energy compromise in disease pathogenesis Hum Mol Genet. 10:2001;1215-1220.
37. Gollob M.H., Seger J.J., Gollob T.N., Tapscott T., Gonzales O., Bachinski L.et al. PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation. 104:2001;3030-3033.
38. Arad M., Benson D.W., Perez-Atayde A.R., McKenna W.J., Sparks E.A., Kanter R.J.et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest. 109:2002;357-362.
39. Hawley S.A., Selbert M.A., Goldstein E.G., Edelman A.M., Carling D., Hardie D.G. 5′AMP activates the AMP-activated protein kinase cascade, and Ca2+/Calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J Biol Chem. 270:1995;27186-27191.
40. Hamilton S.R., O'Donnell J.B. Jr., Hammet A., Stapleton D., Habinowski S.A., Means A.R.et al. AMP-activated protein kinase kinase. detection with recombinant AMPK α1 subunit Biochem. Biophys. Res. Commun. 293:2002;892-898.
41. Daniel T., Carling D. Expression and regulation of the AMP-activated protein kinase/SNF1 kinase complexes in yeast and mammalian cells. Studies using chimeric catalytic subunits. Biochem. J. 365:2002;629-638.
42. Altarejos J.Y., Taniguchi M., Lopaschuk G.D. 5′AMP-activated protein kinase kinase (AMPKK) is expressed in the heart and is activated during ischemia. Circulation. 102(II):2000;345.
43. Bak M.I., Ingwall J.S. Regulation of cardiac AMP-specific 5′-nucleotidase during ischemia mediates ATP resynthesis on reflow. Am. J. Physiol. 274:1998;C992-C1001.
44. Coven D.L., Hu X., Sinusas A.J., Bergeron R., Carling D., Young L.H. Activation of both α1 and α2 isoforms of AMP-activated protein kinase occurs during in vivo myocardial ischemia. Circulation. 102(II):2000;344.
45. Salt I.P., Celler J.W., Hawley S.A., Prescott A., Woods A., Carling D.et al. AMP-activated protein kinase. greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform Biochem. J. 334:1998;177-187.
46. Carling D., Clarke P.R., Zammit V.A., Hardie D.G. Purification and characterization of the AMP-activated protein kinase.Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur J Biochem. 186:1989;129-136.
47. Frederich M., Balschi J.A. The relationship between AMP-activated protein kinase activity and AMP concentration in the isolated perfused rat heart. J Biol Chem. 277(3):2002;1928-1932.
48. Beauloye C., Marsin A.S., Bertrand L., Krause U., Hardie D.G., Vanoverschelde J.-L.et al. Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. FEBS Lett. 505:2001;348-352.
49. Neely J.R., Morgan H.E. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol. 36:1974;413-457.
50. Stanley W.C., Lopaschuk G.D., Hall J.L., McCormack J.G. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Potential for pharmacological interventions. Cardiovasc Res. 33:1997;243-257.
51. Brownsey R.W., Boone A.N., Allard M.F. Actions of insulin on mammalian heart. metabolism, pathology and biochemical mechanisms Cardiovasc Res. 34:1997;3-24.
52. Marshall R.C., Tillisch J.H., Phelps M.E., Huang S.C., Carson R., Henze E.et al. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography, 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation. 67:1983;766-778.
53. King L.M., Opie L.H. Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with a residual coronary flow. Cardiovas Res. 39:1998;381-392.
54. Stanley W.C., Hall J.L., Stone C.K., Hacker T.A. Acute myocardial ischemia causes a transmural gradient in glucose extraction but not glucose uptake. Am. J. Physiol. 262:1992;H91-H96.
55. Woods A., Azzout-Marniche D., Foretz M., Stein S.C., Lemarchand P., Ferre P.et al. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol. 20:2000;6704-6711.
56. Hayashi T., Hirshman M.F., Fujii N., Habinowski S.A., Witters L.A., Goodyear L.J. Metabolic stress and altered glucose transport. Diabetes. 49:2000;527-531.
57. Barnes K., Ingram J.C., Porras O.H., Barros L.F., Hudson E.R., Fryer L.G.D.et al. Activation of GLUT-1 by metabolic and osmotic stress. potential involvement of AMP-activated protein kinase (AMPK) J Cell Sci. 115:2002;2433-2442.
58. Tian R., Musi N., D'Agostino J., Hirshman M.F., Goodyear L.J. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation. 104:2001;1664-1669.
59. Russell R.R. III., Bergeron R., Shulman G.I., Young L.H. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol. 277:1999;H643-H649.
60. Fraser H., Lopaschuk G.D., Clanachan A.S. Alteration of glycogen and glucose metabolism in ischemic and post-ischemic working rat hearts by adenosine A1 receptor stimulation. Brit J Pharmacol. 128:1999;197-205.
61. Young L.H., Renfu Y., Russel R., Hu X., Caplan M., Ren J.et al. Low-flow ischemia leads to translocation of canine heart Glut-4 and Glut-1 glucose transporters to the sarcolemma in vivo. Circulation. 95:1997;415-422.
62. Patel N., Khayat Z.A., Ruderman N.B., Klip A. Dissociation of 5′AMP-activated protein kinase activation and glucose uptake stimulation by mitochondrial uncoupling and hyperosmolar stress. Differential sensitivities to intracellular Ca2+ and protein kinase C inhibition Biochem. Biophys. Res. Commun. 285:2001;1066-1070.
63. Holmes B.F., Kurth-Kraczec E.J., Winder W.W. Chronic activation of 5′AMP-activated protein kinase increases GLUT-4, hexokinase and glycogen in muscle. J Appl Physiol. 87:1999;1990-1995.
64. Zheng D., MacLean P.S., Pohnert S.C., Knight J.B., Olson L., Winder W.W.et al. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J Appl Physiol. 91:2001;1073-1083.
65. Mu J., Brozinick J.T. Jr., Valladares O., Bucan M., Bairnbaum M.J. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell. 7:2001;1085-1094.
66. Fryer L.G.D., Foufelle F., Barnes K., Baldwin S.A., Woods A., Carling D. Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose transport in skeletal muscle cells. Biochem. J. 363:2002;167-174.
67. Fisher J.S., Gao J., Han D.-O., Holloszy J.O., Nolte L.A. Activation of AMP-kinase enhances sensitivity of muscle glucose transport to insulin. Am. J. Physiol. 282:2002;E18-E23.
68. Jakobsen S.N., Hardie D.G., Morrice N., Tornqvist H.E. AMPK phosphorylates IRS-1 on Ser789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem. 276:2001;46912-46916.
69. Chen H.C., Bandyopadhyay G., Sajan M.P., Kanoh Y., Standaert M., Farese R.V.et al. Activation of the ERK pathway and atypical protein kinase C isoforms in exercise-and AICAR-stimulated glucose transport. J Biol Chem. 277:2002;23554-23562.
70. Chen Z.-P., McConnel G.K., Michell B.J., Snow R.J., Canny B.J., Kemp B.E. AMPK signaling in contracting human skeletal muscle. acetyl CoA carboxylase and NO synthase phosphorylation Am. J. Physiol. 279:2000;E1202-E1206.
71. Opie L.H. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction.Relation to myocardial ischemia and infarct size. Am J Cardiol. 36:1975;938-953.
72. Mueller H.S., Ayres S.T. Metabolic response of the heart in acute myocardial infarction in man. Am J Cardiol. 42:1978;363-371.
73. Lopaschuk G.D., Collins-Nakai R., Olley P.M., Montague T.J., McNeil G., Gayle M.et al. Plasma fatty acid levels in infants and adults after myocardial ischemia. Am Heart J. 128:1994;61-67.
74. Lopaschuk G.D., Wall S.R., Olley P.M., Davies N.J. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 63:1988;1036-1043.
75. Lopaschuk G.D., Saddik M., Barr R., Huang L., Barker C., Muzyka R.A. Effects of high levels of fatty acids on functional recovery of ischemic hearts from diabetic rats. Am. J. Physiol. 263:1992;E1046-E1053.
76. Sakamoto J., Barr R.L., Kavanagh K.M., Lopaschuk G.D. Contribution of malonyl-CoA decarboxylase to the high fatty acid oxidation rates seen in the diabetic heart. Am. J. Physiol. 278:2000;H1196-204.
77. Hardie D.G. Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase. Biochim Biophys Acta. 123:1992;231-238.
78. Kim K.H., Lopez-Casillas F., Bai D.H., Luo X., Pape M.E. Role of reversible phosphorylation of acetyl-CoA carboxylase in long-chain fatty acid synthesis. FASEB J. 3:1989;2250-2256.
79. Awan M.M., Saggerson E.D. Malonyl-CoA metabolism in cardiac myocytes and its relevance to the control of fatty acid oxidation. Biochem. J. 295:1993;61-66.
80. Dyck J.R.B., Kudo N., Barr A.J., Davies S.P., Hardie D.G., Lopaschuk G.D. Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5′-AMP activated protein kinase. Eur J Biochem. 262:1999;184-190.
81. Abu-Elheiga L., Almarza-Ortega D.B., Baldin A., Wakil S.J. Human Acetyl-CoA Carboxylase 2. Molecular cloning, characterization, chromosomal mapping, and evidence for two isoforms J Biol Chem. 272:1997;10669-10677.
82. Kim J.M., Yoon M., Kang I., Kim S.S., Ha J. Evidence that acetyl-CoA carboxylase isoforms play different biological roles in H9c2 cardiomyocytes. Biochem. Biophys. Res. Commun. 248:1998;490-496.
83. Winder W.W., Wilson H.A., Hardie D.G., Rasmussen B.B., Hutber C.A., Call G.B.et al. Phosphorylation of rat skeletal muscle acetyl-CoA carboxylase by AMP-activated protein kinase and Protein kinase A. J Appl Physiol. 82:1997;219-225.
84. Boon A.N., Rodrigues B., Brownsey R.W. Multiple site phosphorylation of 280 kDa isoform of acetyl-CoA carboxylase in rat cardiac myocytes. evidence that cAMP-dependent protein kinase mediates effects of -adrenergic stimulation Biochem. J. 341:1999;347-354.
85. Gamble J., Lopaschuk G.D. Insulin inhibition of 5′AMP-activated protein kinase in the heart results in activation of acetyl-CoA carboxylase and inhibition of fatty acid oxidation. Metabolism. 46:1997;1270-1274.
86. Park S.H., Gammon S.R., Knippers J.D., Paulsen S.R., Rubink D.S., Winder W.W. Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol. 92:2002;2475-2482.
87. Makinde A.-O., Gamble J., Lopaschuk G.D. Upregulation of 5′-AMP- activated protein kinase is responsible for the increase in myocardial fatty acid oxidation rates following birth in the newborn rabbit. Circ Res. 80:1997;482-489.
88. Saha A.K., Schwarsin A.J., Roduit R., Masse F., Kaushik V., Tornheim K.et al. Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside. J Biol Chem. 275:2000;24279-24283.
89. Park H., Kaushik V.K., Constant S., Prentki M., Przybytkowski E., Ruderman N.B.et al. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem. 277:2002;32571-32577.
90. Habinowski S.A., Hirshman M., Sakamoto K., Kemp B.E., Gould S.J., Goodyear L.J.et al. Malonyl-CoA decarboxylase is not a substrate of AMP-activated protein kinase in rat fast-twitch skeletal muscle or an islet cell line. Arch. Biochem. Biophys. 396:2001;71-79.
91. Minokoshi Y., Kim Y.-B., Peroni O.D., Fryer L.G.D., Muller C., Carling D.et al. Leptin stimulates fatty acid oxidation by activating AMP-activated protein kinase. Nature. 415:2002;339-343.
92. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J.et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:2001;1167-1174.
93. Fryer L.G.D., Parbu-Patel A., Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 277:2002;25226-25232.
94. Tian R., Musi N., D'Agostino J., Hirshman M.F., Goodyear L.J. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure overload hypertrophy. Circulation. 104:2001;1664-1669.
95. Aschenbach W.G., Hirshman M.F., Fujii N., Sakamoto K., Howlett K.P., Goodyear L.J. Effect of AICAR treatment on glycogen metabolism in skeletal muscle. Diabetes. 51:2002;567-573.
96. Gollob M.H. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Eng J Med. 344:2001;1823-1831.